Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus COR OTICIN.
CAPEX vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic